Safety Shot Inc (SHOT)
USD 0.48
(-9.45%)
USD 0.48
(-9.45%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 202.67 Thousand USD | -96.73% |
| 2022 | 6.19 Million USD | 115.44% |
| 2021 | 2.87 Million USD | 169.9% |
| 2020 | 1.06 Million USD | 16409.14% |
| 2019 | 6455.00 USD | 0.0% |
| 2018 | - USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 710.24 Thousand USD | 316.0% |
| 2024 Q1 | 170.73 Thousand USD | 28.66% |
| 2023 Q1 | 1.12 Million USD | 23.86% |
| 2023 Q3 | 484.19 Thousand USD | -79.53% |
| 2023 FY | 202.67 Thousand USD | -96.73% |
| 2023 Q4 | 132.7 Thousand USD | -72.59% |
| 2023 Q2 | 2.36 Million USD | 110.87% |
| 2022 FY | 6.19 Million USD | 115.44% |
| 2022 Q4 | 905.6 Thousand USD | -42.32% |
| 2022 Q3 | 1.56 Million USD | -47.68% |
| 2022 Q2 | 3 Million USD | 315.81% |
| 2022 Q1 | 721.62 Thousand USD | -53.27% |
| 2021 Q3 | 687.92 Thousand USD | 15.6% |
| 2021 Q4 | 1.54 Million USD | 124.5% |
| 2021 FY | 2.87 Million USD | 169.9% |
| 2021 Q1 | 48.84 Thousand USD | -84.34% |
| 2021 Q2 | 595.08 Thousand USD | 1118.29% |
| 2020 Q4 | 311.93 Thousand USD | 74.92% |
| 2020 Q2 | 457.66 Thousand USD | 288.75% |
| 2020 Q1 | 117.72 Thousand USD | 210126.79% |
| 2020 FY | 1.06 Million USD | 16409.14% |
| 2020 Q3 | 178.33 Thousand USD | -61.03% |
| 2019 Q1 | - USD | 0.0% |
| 2019 Q4 | 56.00 USD | -98.9% |
| 2019 Q3 | 5068.00 USD | 280.77% |
| 2019 FY | 6455.00 USD | 0.0% |
| 2019 Q2 | 1331.00 USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 99.958% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | 99.599% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 99.964% |
| Cosmos Health Inc. | 53.37 Million USD | 99.62% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | 81.172% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | 99.826% |
| Cronos Group Inc. | 88.84 Million USD | 99.772% |
| Incannex Healthcare Limited | 12 Thousand USD | -1588.917% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | 99.842% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | 99.159% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | 99.159% |
| SCYNEXIS, Inc. | 140.14 Million USD | 99.855% |
| Theratechnologies Inc. | 81.76 Million USD | 99.752% |
| Alpha Teknova, Inc. | 36.68 Million USD | 99.448% |
| Universe Pharmaceuticals INC | 32.3 Million USD | 99.373% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 99.97% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | 98.409% |
| Dynavax Technologies Corporation | 232.28 Million USD | 99.913% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 99.954% |
| Radius Health, Inc. | 2.88 Billion USD | 99.993% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | 89.491% |
| Alvotech | 91.43 Million USD | 99.778% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 99.956% |
| SIGA Technologies, Inc. | 139.91 Million USD | 99.855% |
| Shineco, Inc. | 9.8 Million USD | 97.932% |
| Silver Spike Investment Corp. | 11.72 Million USD | 98.271% |
| Journey Medical Corporation | 79.18 Million USD | 99.744% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | 96.519% |
| Embecta Corp. | 1.12 Billion USD | 99.982% |
| Harrow Health, Inc. | 130.19 Million USD | 99.844% |
| Procaps Group, S.A. | 409.92 Million USD | 99.951% |
| Biofrontera Inc. | 34.07 Million USD | 99.405% |
| DURECT Corporation | 8.54 Million USD | 97.629% |
| PainReform Ltd. | - USD | -Infinity% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 99.967% |
| OptiNose, Inc. | 70.98 Million USD | 99.714% |
| RedHill Biopharma Ltd. | 6.51 Million USD | 96.888% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 99.953% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | 99.488% |
| ProPhase Labs, Inc. | 44.38 Million USD | 99.543% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 99.98% |
| Procaps Group S.A. | 409.92 Million USD | 99.951% |
| TherapeuticsMD, Inc. | 1.3 Million USD | 84.434% |
| Viatris Inc. | 15.42 Billion USD | 99.999% |
| Rockwell Medical, Inc. | 83.61 Million USD | 99.758% |
| Aytu BioPharma, Inc. | 81 Million USD | 99.75% |
| Tilray Brands, Inc. | 788.94 Million USD | 99.974% |
| PetIQ, Inc. | 1.1 Billion USD | 99.982% |
| Talphera, Inc. | 651 Thousand USD | 68.868% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 99.989% |
| Alimera Sciences, Inc. | 80.75 Million USD | 99.749% |
| Assertio Holdings, Inc. | 152.06 Million USD | 99.867% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | 99.275% |
| Hempacco Co., Inc. | 4.04 Million USD | 94.99% |
| Alvotech | 91.43 Million USD | 99.778% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 99.984% |
| Kamada Ltd. | 144.75 Million USD | 99.86% |
| Currenc Group, Inc. | 53.25 Million USD | 99.619% |
| Indivior PLC | 1.09 Billion USD | 99.981% |
| Evoke Pharma, Inc. | 5.18 Million USD | 96.088% |
| Flora Growth Corp. | 76.07 Million USD | 99.734% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | 81.172% |
| Evolus, Inc. | 202.08 Million USD | 99.9% |
| HUTCHMED (China) Limited | 837.99 Million USD | 99.976% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 99.969% |
| Akanda Corp. | 2.16 Million USD | 90.617% |